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VEGF-C and 
-D in renal 
lymphangiogenesis
Lymphatic vessels undergo remodeling 
following tissue injury, and macrophages 
have been shown to have an important 
role in this response. However, the 
regulation of lymphangiogenesis in 
renal injury is poorly understood. As 
they report in this issue, Lee and col-
leagues studied lymphangiogenesis in 
kidney fibrosis and the roles of vascular 
endothelial growth factor-C (VEGF-C) 
and VEGF-D in lymphangiogenesis fol-
lowing unilateral ureteral obstruction 
(UUO). UUO increased renal lymphan-
giogenesis and lymphatic expression 
of VEGF-C and -D, and macrophage 
depletion reduced UUO-induced lymph-
angiogenesis. Interestingly, VEGF-C 
expression was higher in M2 than in M1 
macrophages, and transforming growth 
factor-b1 and tumor necrosis factor-a 
increased macrophage VEFG-C expres-
sion. Further, the authors demonstrated 
important roles for VEFG-C and -D in 
promoting UUO-induced lymphangio-
genesis. These data shed new light on the 
mechanisms by which new lymphatic 
vessels form in the setting of renal 
fibrosis. See page 50.
In vivo mitochondrial 
imaging in acute 
kidney injury
Mitochondrial injury is an important 
contributor to acute kidney injury (AKI) 
due to many etiologies. Mitochondrial 
structural and functional changes are 
highly dynamic, and new methods are 
needed to study them in vivo. Thus, Hall 
et al. used multiphoton microscopy to 
image mitochondria in renal tubules 
of living mice and rats after ischemia–
reperfusion injury and gentamicin 
administration. Using a combination 
of endogenous and exogenous fluoro-
phores, they visualized mitochondrial 
morphology, membrane potential, and 
NAD+ accumulation in real time and 
compared these changes between dif-
ferent nephron segments. These exciting 
data provide researchers with novel 
approaches to elucidate the mechanisms 
of AKI and test new strategies to prevent 
and treat AKI. See page 72.
APOL1 variants and 
hypertensive CKD  
in African Americans
APOL1 polymorphisms confer resis-
tance to trypanosomal infection at 
the expense of increasing risk of non-
diabetic end-stage renal disease, but 
the risk of less advanced chronic 
kidney disease (CKD) attributable to 
APOL1 variants is not well understood. 
Lipkowitz et al. studied whether poly-
morphisms in the APOL1 locus are 
associated with hypertensive CKD in 
the African American Study of Kidney 
Disease and Hypertension. They 
report that APOL1 risk variants were 
associated with an odds ratio of 2.6 for 
hypertensive CKD, and the association 
was stronger for more advanced CKD. 
Importantly, APOL1 risk variants did 
not modify the response to different 
blood pressure targets and classes of 
blood pressure medications. This study 
is the first to examine APOL1-attribut-
able CKD and the effect of genotype on 
treatment response in the context of a 
large randomized trial. See page 114.
Angiotensin II 
receptor blocker  
and calcium blockers 
for hypertensive  
CKD patients
Ang i ote ns i n  re c e ptor  b l o cke rs 
(ARBs) are commonly used to treat 
hypertension, especially in patients with 
CKD. In the Olmesartan and Calcium 
Antagonists Randomized (OSCAR) 
Study, investigators compared ARB 
plus calcium channel blocker (CCB) 
combination therapy versus high-
dose ARB in elderly Japanese patients 
with hypertension and basel ine 
cardiovascular disease and/or diabetes. 
In this issue, OSCAR investigators report 
the results of a prespecified analysis of 
the effect of the study interventions in 
patients with baseline CKD. Patients 
in the high-dose ARB group had a 
2.25-fold increased risk of the primary 
composite outcome of cardiovascular 
events and cardiovascular death and 
also had higher rates of cerebrovascular 
and heart  fai lure events .  These 
important data suggest that ARB/CCB 
combination therapy may be superior to 
high-dose ARB in elderly CKD patients 
with cardiovascular disease or diabetes. 
See page 167.
